Ginkgo Bioworks beats Q3 revenue estimates, advancing autonomous lab strategy
DNA Ginkgo Bioworks Holdings Inc
$12.01 -2.91%
View chart & analysis → - 1Ginkgo Bioworks recorded Q3 revenue of $27.71 million, exceeding estimates by 35.2%.
- 2Novo Nordisk purchased its first autonomous lab for the Waltham R&D site.
- 3Ginkgo Bioworks reported a loss of $0.64 per share, missing Q3 EPS estimates by 10.3%.
So what's the key point?
Ginkgo Bioworks generated more revenue than expected. The company's business is progressing as Novo Nordisk purchased its laboratory equipment.
Source Earnings Whispers · View original ↗
Today's 5 AI picks, all freeNothing hidden: past picks and how they did against the S&P 500.